Reshma Kewalramani, Vertex CEO (Photo by Barry Chin/The Boston Globe via Getty Images)

In a world first, Ver­tex, CRISPR win UK ap­proval for CRISPR-edit­ed ther­a­py to treat sick­le cell dis­ease, be­ta-tha­lassemia

Ver­tex and CRISPR Ther­a­peu­tics have won the first-ever ap­proval for a ther­a­py cre­at­ed with CRISPR gene edit­ing, as the UK drug reg­u­la­tor MHRA green­lights their treat­ment for two blood dis­or­ders.

The ther­a­py pre­vi­ous­ly known as exa-cel will now be brand­ed Cas­gevy. It is au­tho­rized to treat sick­le cell dis­ease and trans­fu­sion-de­pen­dent be­ta-tha­lassemia.

“To­day is a his­toric day in sci­ence and med­i­cine: this au­tho­riza­tion of Cas­gevy in Great Britain is the first reg­u­la­to­ry au­tho­riza­tion of a CRISPR-based ther­a­py in the world,” said Ver­tex CEO Resh­ma Ke­wal­ra­mani in a Tues­day state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.